Fig. 7

Immunotherapeutic benefits of LINC01133. A Immune score, stromal score and estimate score between high-/low- LINC01133 groups. B Gene expression of immune checkpoints between high-/low- LINC01133 groups. C Bar graph showed the distribution of PD and CR/PR in high- / low- LINC01133 groups. D Kaplan–Meier curve of OS for patients with high and low LINC01133 groups for GSE78220 cohort. E Boxplot graph illustrated the expression level of LINC01133 between PD and CR/PR groups. Statistical significance at the level of ns ≥ 0.05, ^∗ < 0.05, ^∗∗ < 0.01 and ^∗∗∗ < 0.001. PD: progressive disease; CR: complete response; PR: partial response